Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III faricimab study in angioid streaks
jRCT2071220090Phase 3Active, not recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Mar 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of faricimab in angioid streaks, sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Change from baseline in BCVA score at Week 12. Started Mar 2023; status: active, not recruiting.
02
Drugs
faricimab
03
Conditions
angioid streaks
Beyond the preview
Go deeper on jRCT2071220090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071220090.